PIN18 - COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES.
Saved in:
| Title: | PIN18 - COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES. |
|---|---|
| Authors: | Gallant, J.1, Altice, F.2, Folse, H.J.3 |
| Source: | Value in Health. May2016, Vol. 19 Issue 3, pA214-A214. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10983015 |
|---|---|
| DOI: | 10.1016/j.jval.2016.03.1206 |
